New antibody-drug conjugate research partnership announced

AB SCIEX and Dalton Pharma Services announced that they are joining forces on R&D for antibody-drug conjugate analysis capabilities. "A key challenge for developing successful antibody-drug conjugate medicines is understanding the structure and payload of the final molecule. Determining where the drug attaches to a particular antibody early in its development and the number of drug molecules on the antibody are important indicators of the likely success of a new ADC," explained Tan Quach, Chemistry Manager at Dalton Pharma Services. The companies hope that their collaboration will lead to breakthrough research on ADC. Release